Acute promyelocytic leukemia successfully treated also in elderly patients with significant comorbidities: a 20-year single-center experience

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F15%3A33150782" target="_blank" >RIV/61989592:15110/15:33150782 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00098892:_____/15:#0000898

Výsledek na webu

<a href="http://dx.doi.org/10.4149/neo_2015_019" target="_blank" >http://dx.doi.org/10.4149/neo_2015_019</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4149/neo_2015_019" target="_blank" >10.4149/neo_2015_019</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Acute promyelocytic leukemia successfully treated also in elderly patients with significant comorbidities: a 20-year single-center experience

Popis výsledku v původním jazyce

Acute promyelocytic leukemia is a unique entity among acute leukemias. Introduction of all-trans retinoic acid and, subsequently, arsenic trioxide in its treatment has markedly improved treatment outcomes for this once frequently fatal disease. Improvedoutcomes have also been observed in elderly patients, including those in whom standard intensive therapy is contraindicated because of comorbidities. In our center, a total of 60 APL patients were treated in 1993-2013, of whom 9 were aged 60 or more years. Although most of them had significant comorbidities at the time of diagnosis, eight achieved complete remission. At the time of the analysis, six patients were alive and in long-term remission; two patients died of causes other than APL. The median follow-up was 59 months. Included is case report of a patient with a high comorbidity score whose treatment was markedly reduced and individualized. Our experience shows that, in APL patients a curative approach is generally tolerated and s

Název v anglickém jazyce

Acute promyelocytic leukemia successfully treated also in elderly patients with significant comorbidities: a 20-year single-center experience

Popis výsledku anglicky

Acute promyelocytic leukemia is a unique entity among acute leukemias. Introduction of all-trans retinoic acid and, subsequently, arsenic trioxide in its treatment has markedly improved treatment outcomes for this once frequently fatal disease. Improvedoutcomes have also been observed in elderly patients, including those in whom standard intensive therapy is contraindicated because of comorbidities. In our center, a total of 60 APL patients were treated in 1993-2013, of whom 9 were aged 60 or more years. Although most of them had significant comorbidities at the time of diagnosis, eight achieved complete remission. At the time of the analysis, six patients were alive and in long-term remission; two patients died of causes other than APL. The median follow-up was 59 months. Included is case report of a patient with a high comorbidity score whose treatment was markedly reduced and individualized. Our experience shows that, in APL patients a curative approach is generally tolerated and s

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)<br>S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Neoplasma

ISSN

0028-2685

e-ISSN

—

Svazek periodika

62

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

SK - Slovenská republika

Počet stran výsledku

6

Strana od-do

146-151

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—